SOURCE: IO News Wire

September 06, 2011 07:30 ET

Unilife Develops Proprietary Self-Injection System

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO News Wire

NEW YORK, NY--(Marketwire - Sep 6, 2011) - Unilife Corp (NASDAQ: UNIS) has announced it has developed the first retracting, self-injector for use with self-administration injectable drugs by patients outside of a healthcare facility setting.

Many companies either develop their own proprietary self-injectors like Antares Pharma (NYSE Amex: AIS) and Becton, Dickinson (NYSE: BDX) or they invest in companies that develop the technology, like GlaxoSmithKline (NYSE: GSK). Unilife has developed their auto-injector for use with their Unifill syringe, the needle retracts after use after an audible-tactile click when the end of the dose is reached. This ensures the patient receives the full amount of the drug being injected.

This gives Unilife a fully integrated system for a patient to use in conjunction with Unifill prefilled syringes.

To find out more, please visit

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information